Alessio Cortellini, Consultant Medical Oncologist and Assistant Professor at Campus Bio-Medico University of Rome, shared a post on X:
“Suppression or eradication?
An early question in ADAURA and adjuvant TKIs in NSCLC.
At 8 years, adjuvant osimertinib maintains an OS benefit (79% vs 64%; HR 0.52), 5 years beyond treatment completion. Not proof of eradication, but increasingly hard to explain by delayed recurrence alone.”
Title: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial
Authors: Yi-Long Wu, Margarita Majem, Thomas John, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lu, Frances A. Shepherd, Qun Wang, Terufumi Kato, Keiju Aokage, Wen-Zhao Zhong, Konstantin Laktionov, Ming-Fang Wu, Charuwan Akewanlop, Huu Vinh Vu, Ki Hyeong Lee, Xiangning Huang, Elena Armenteros-Monterroso, Yuri Rukazenkov, Roy S. Herbst.
Read the full article in the Journal of Thoracic Oncology.
Find out more:
